XML 52 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 
Three Months Ended   
June 30,
 
Six Months Ended   
June 30,
 
2018
 
2017
 
2018
 
2017
Segment Net Sales
 

 
 

 
 

 
 

United States
$
512.2

 
$
478.9

 
$
991.7

 
$
943.5

Europe
211.2

 
181.2

 
416.5

 
446.5

Japan
101.9

 
91.3

 
193.0

 
173.1

Rest of World
101.7

 
92.5

 
193.4

 
174.3

Total segment net sales
$
927.0

 
$
843.9

 
$
1,794.6

 
$
1,737.4

Segment Operating Income
 

 
 

 
 

 
 

United States
$
343.7

 
$
314.7

 
$
657.5

 
$
618.2

Europe
101.7

 
79.5

 
204.7

 
231.6

Japan
62.0

 
52.8

 
116.8

 
98.8

Rest of World
32.3

 
27.3

 
61.3

 
52.7

Total segment operating income
$
539.7

 
$
474.3

 
$
1,040.3

 
$
1,001.3


The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 
Three Months Ended   
June 30,
 
Six Months Ended   
June 30,
 
2018
 
2017
 
2018
 
2017
Net Sales Reconciliation
 

 
 

 
 

 
 

Segment net sales
$
927.0

 
$
843.9

 
$
1,794.6

 
$
1,737.4

Foreign currency
16.7

 
(2.1
)
 
43.9

 
(12.1
)
Consolidated net sales
$
943.7

 
$
841.8

 
$
1,838.5

 
$
1,725.3

Pre-tax Income Reconciliation
 

 
 

 
 

 
 

Segment operating income
$
539.7

 
$
474.3

 
$
1,040.3

 
$
1,001.3

Unallocated amounts:
 

 
 

 
 

 
 

Corporate items
(277.6
)
 
(223.6
)
 
(525.7
)
 
(442.2
)
Intellectual property litigation expenses
(5.5
)
 
(7.7
)
 
(11.2
)
 
(17.9
)
Foreign currency
(4.5
)
 
(2.0
)
 
1.2

 
(1.9
)
Consolidated operating income
252.1

 
241.0

 
504.6

 
539.3

Non-operating income (expense)
(1.1
)
 
(35.4
)
 
9.9

 
(40.1
)
Consolidated pre-tax income
$
251.0

 
$
205.6

 
$
514.5

 
$
499.2

Enterprise-Wide Information
Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 
Three Months Ended   
June 30,
 
Six Months Ended   
June 30,
 
2018
 
2017
 
2018
 
2017
 
(in millions)
 
 
 
 
Net Sales by Geographic Area
 

 
 

 
 

 
 

United States
$
512.1

 
$
478.9

 
$
991.6

 
$
943.5

Europe
228.0

 
183.7

 
458.0

 
444.7

Japan
102.6

 
90.5

 
195.3

 
169.8

Rest of World
101.0

 
88.7

 
193.6

 
167.3

 
$
943.7

 
$
841.8

 
$
1,838.5

 
$
1,725.3

Net Sales by Major Product and Service Area
 

 
 

 
 

 
 

Transcatheter Heart Valve Therapy
$
584.9

 
$
487.5

 
$
1,136.5

 
$
1,026.7

Surgical Heart Valve Therapy
190.3

 
207.1

 
369.8

 
406.6

Critical Care
168.5

 
147.2

 
332.2

 
292.0

 
$
943.7

 
$
841.8

 
$
1,838.5

 
$
1,725.3


 
June 30, 2018
 
December 31, 2017
 
(in millions)
Long-lived Tangible Assets by Geographic Area
 

 
 

United States
$
593.7

 
$
608.7

Europe
30.0

 
28.4

Japan
7.3

 
7.6

Rest of World
169.7

 
139.7

 
$
800.7

 
$
784.4